Cincinnati Children’s has been a leader in basic science and clinical research for decades. Through scientific discovery, innovation and multidisciplinary collaboration, our researchers are pursuing new clues about the causes of cancer and developing more effective targeted therapies. In 2009, we established the Cancer and Blood Diseases Institute (CBDI) to formally align our strong clinical care and research programs, enhancing collaborations and speeding the transfer of knowledge from the lab bench to the patient’s bedside.

Basic Research

Scientific inquiry drives the creation of knowledge. To this end, researchers in CBDI’s Division of Experimental Hematology and Cancer Biology explore how abnormalities in our genetic code and cell signaling pathways contribute to the development of cancer and blood diseases. Under the leadership of director Yi Zheng, PhD, these researchers seek to understand the mechanisms of blood diseases and cancer and lay the foundation for exciting new approaches to diagnosing, treating and even curing some of the most serious diseases of childhood and young adulthood. Read more about the Zheng Research Lab.

Translational and Clinical Research

CBDI promotes close collaborations between basic scientists and the physicians who care for our patients. Our doctors partner with researchers and clinicians in other divisions, including developmental biology, immunology and radiology. What we learn in the lab can have a significant impact on patient care, and insights from the clinic can prompt investigations in the lab. Our doctors are leaders in national consortia developing new therapies for cancer, blood diseases and immune disorders. This allows our patients to have early access to new therapies, sometimes years before they are available at other centers.

What Sets Our Research Program Apart

  • Well-established clinical researchers, who provide leadership for national studies
  • Leading-edge laboratory research that focuses on stem cell biology, molecular and gene therapy, leukemia biology, cell signaling, cancer biology and pathology and the use of genetically reprogrammed viruses to kill tumors
  • State-of-the-art technology, including special programs to support gene and cellular therapy initiatives
  • The ability to transfer laboratory breakthroughs to the patient care setting
  • Patient access to novel therapies, sometimes years before they are widely available
  • A commitment to educate and train researchers of the future, through fellowships, seminars and other opportunities
  • Contributions to the worldwide research community through extensive publication of research findings